Vogt Koyanagi Harada Disease
Conditions
Keywords
Vogt-koyanagi Harada, Suprachoroidal injection
Brief summary
Suprachoroidal injection, a novel technique for delivering ocular therapies, may facilitate targeted therapeutic delivery to the choroidal and retinal structures than intravitreal injection
Detailed description
Suprachoroidal injection, a novel technique for delivering ocular therapies, may facilitate targeted therapeutic delivery to the choroidal and retinal structures than intravitreal injection. Yielding high levels of corticosteroid in the retinal and choroidal layers which was detectable for more than 3 months with limited exposure in the anterior segment. Triamcinolone acetonide is a synthetic corticosteroid formulated as an injectable suspension and has been evaluated in a number of trials to be 7.5 fold more potent anti-inflammatory than cortisone. Triamcinolone acetonide enhance tight junctions between endothelial cells thus reducing vessel leakage. It also has an angiostatic action by inhibition of vascular endothelial growth factor and has a useful effect on many inflammatory retinal diseases. The recommended dose of Triamcinolone acetonide injection is 4 mg/0.1 mL which was administrated in this study. The aim of this study was to assess the efficacy of suprachoroidal Triamcinolone acetonide injection (SCTA) as adjunctive therapy in the management of Vogt-Koyanagi Harada's (VKH) multiple serous retinal detachment (RD) and evaluate best corrected visual acuity (BCVA), intraocular pressure(IOP) and central foveal thickness (CFT) by Optical Coherence Tomography (OCT) in patients diagnosed as VKH at ophthalmology clinic, Benha University, EGYPT and Ebsar eye center, Benha, EGYPT.
Interventions
DRUGSuprachoroidal Triamcinolone acetonide injection for serous retinal detachment in VKH disease
Suprachoroidal steroid injection for management of serous retinal detachment in VKH disease
Sponsors
Benha University
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
47 Years to 52 Years
Healthy volunteers
No
Inclusion criteria
* patients diagnosed as VKH serous retinal detachment in the acute phase whom BCVA is not improving after 2 weeks from starting systemic steroids.
Exclusion criteria
* recent intraocular surgery. * patients refuse to participate in the study. * media opacity and other causes of serous retinal detachment than VKH.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Best Corrected Visual Acuity (LogMAR units) | 6 months after injection | Changes in vision from baseline upto 6 months follow up |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Central Foveal Thickness measured by Optical Coherence Tomography | Upto 6 months after SCTA injection | Changes in CFT during 6 months after injection |
Other
| Measure | Time frame | Description |
|---|---|---|
| Intraocular pressure measured by Goldmann applanation tonometry | 6 months after injection | Changes in IOP during 6 months follow up |
Countries
Egypt
Outcome results
None listed